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Pilocytic astrocytoma (PA) is the most frequently occurring brain
tumour in childhood. It is classified as grade I by the World Health
Organization and does not tend to evolve into higher-grade
tumours (Giannini and Scheithauer, 1997). Very little is currently
known of the genetic abnormalities involved in the development
of PA. More than 120 cases have been analysed cytogenetically,
but no consistent abnormality has been identified. Of 119 paedi-
atric cases examined, 38 showed detectable chromosomal abnor-
malities; eight adult cases have been examined and seven of these
showed chromosomal abnormalities (Jenkins et al, 1989; Karnes
et al, 1992; Ransom et al, 1992; Thiel et al, 1992; Ganju et al,
1994; Agamanolis and Malone, 1995; Debiec-Rychter et al, 1995;
White et al, 1995; Bhattacharjee et al, 1997; Bigner et al, 1997;
Zattara-Cannoni et al, 1998).
Only a small number of studies of molecular genetic abnormali-
ties in PA has been undertaken to date. The cases included in these
studies were either all paediatric or the patient age was not speci-
fied. Allelic loss has been reported on 17p, including at the TP53
locus, although very few TP53 mutations have been found (von
Deimling et al, 1993; Lang et al, 1994; al-Sarraj et al, 1995; Phelan
et al, 1995; Willert et al, 1995; Patt et al, 1996). Losses on 17q
have also been found, and in some cases these encompassed
the NF1 locus (von Deimling et al, 1993; Platten et al, 1996).
However, no NF1 mutations were observed by single-strand
conformation polymorphism analysis of 16 PA tumours
(Scheurlen and Senf, 1995). A single case of PA was reported to
have a non-sense mutation of PTEN, a gene that is frequently
mutated in glioblastomas (Duerr et al, 1998). No other gene
mutations have been reported and no loci have been shown to be
consistently abnormal in PA.
We have used comparative genomic hybridization (CGH) to
screen for gross genomic copy number abnormalities in PAs from
48 patients. CGH enables the analysis of copy number imbalances
across the genome in a single hybridization and avoids the need
for cell culture (Kallioniemi et al, 1992).
MATERIALS AND METHODS
Tumour specimens
We studied archival frozen tumour tissue from patients operated at
Karolinska Hospital Stockholm, Sahlgrenska Hospital Gothen-
burg and Addenbrooke’s Hospital Cambridge. The clinical and
histopathological data are summarized in Table 1. Of the 48 indi-
vidual tumours studied, 41 were from patients less than 18 years of
age and seven were from adults. We used the suffix ‘a’ to indicate
tumour from primary operations and ‘b’ to indicate tumour from
re-operations. Specimens PA8b, PA9b, PA45b, PA50b and PA53b
were re-operated tumours for which tissue samples from the
primary operation were not available.
DNA extraction
High molecular weight DNA was isolated from the frozen tumour
tissue pieces by homogenization in 4 M guadinium isothiocyanate
buffer followed by ultracentrifugation on a caesium chloride
(CsCl) gradient. The DNA was purified by proteinase K digestion
and phenol–chloroform extraction. Reference genomic DNA was
prepared from blood of one healthy male and one healthy female
donor.
Comparative genomic hybridization
CGH was carried out according to previously published proto-
cols (Kallioniemi et al, 1992), with certain modifications. The
reference and patient genomic DNA were differentially labelled
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by DOP-PCR (Telenius et al, 1992) using biotin-16-dUTP and
fluorescein isothiocyanate (FITC)-dUTP respectively. They were
then co-hybridized onto normal human metaphases. The biotin
label was detected with avidin-Cy3. Twelve to 15 metaphases
were analysed for each specimen using the Vysis Quips CGH
program. The thresholds used for the CGH ratio profiles were 1.2
for gain and 0.8 for loss. Each specimen was analysed at least
twice.
RESULTS
Seven of the 48 tumours showed chromosomal abnormalities
detectable by CGH. A representative copy number karyogram is
shown in Figure 1. In paediatric cases the abnormalities were gains
and involved chromosomes 5, 6, 7, 9 (see Figure 2 for frequency).
No loss of chromosomal regions was detected. Only five of the 41
paediatric tumours (12%) were abnormal. Of the 18 female and 23
male paediatric cases analysed, four female patients and only one
male patient had detectable chromosomal abnormalities. In each
of these only one aberration was seen and this involved the gain of
a single chromosome. Two of the tumours gained a chromosome 7
while the other three gained a chromosome 5, a chromosome 6 or
a chromosome 9.
Of the seven tumours from adult patients two (29%) showed
multiple abnormalities, which included regional copy number
changes as well as gains of whole chromosomes. Of the six
female and one male adult cases only two female patients had
detect-able aberrations. PA 18a had gains of 1p33-pter, 9q34.1-
qter, 17q21.3-pter and whole gains of 19 and 22. PA 34a showed
gains of 2p22-pter, 9q31-qter, 12q13.2-q23, together with loss of
16q.
There was no association between the presence of abnormalities
detectable by CGH and the anatomical location of the tumours.
The five abnormal paediatric cases were located in the posterior
fossa (two cases), optic chiasm, left frontal lobe and hypothalamus
(one case each), while the two abnormal adult cases were located
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Figure 1 CGH interpretation profile of case PA25a. The ration profile was determined from analysis of 12 separate metaphases. As the tumour arose in a
male patient, we utilised control DNA from a female. There is evidence of gain of all of chromosome 9 in the tumour specimen.
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Figure 2 Summary of results from CGH analysis of 48 PA tumours. The top
and bottom boxes show the results from paediatric and adult cases
respectively. Lines to the right of each chromosome in the ideogram depict
regions of DNA gain, whilst lines to the left of each chromosome depict
regions of DNA loss.1220 D Sanoudou et al
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in the pineal region and posterior fossa. Two parts of specimen
PA39a were analysed; interestingly, whereas one of these was
normal, the other showed gain of chromosome 5. In all other
tumours where two specimens were available no abnormalities
were seen in the profiles of either tumour.
DISCUSSION
The majority of cases analysed in this study show no chromosomal
abnormality. Some aberrations, however, are detectable in a
number of different chromosomes. The detectable chromosomal
Table 1 Clinical details relating to PA specimens analysed
Case No Age Sex %tum Tissue Tumour location CGH results
Paediatric cases with normal CGH results
PA2a 5 M 90 Not known  normal
PA5a 3 F 65 cerebellum normal
PA7a 3 F 85 Optic nerve normal
PA8b 8 F 75 Cerebellum, ve normal
PA9b 13 M 85 Hypothalamus normal
PA14a 5 M .90 Posterior fossa normal
PA15a 14 F Not known Vermis normal
PA16a 1 M 85 Hypothalamus normal
PA17a 10 F 80 Posterior fossa normal
PA17b 13 F 75 Posterior fossa normal
PA19a 13 M 80 3rd ventricle normal
PA20a 6 M 90 Posterior fossa normal
PA23a 5 F 90 4th ventricle normal
PA24a 18 M 90 4th ventricle normal
PA28a Not known M .80 Right tempora normal
PA28b Not known M .85 Not known normal
PA29a 15 M 90 Posterior fossa normal
PA30a 16 F 85 Right cerebella normal
PA31a 5 F 90 Brainstem normal
PA32a 4 M Not known 4th ventricle normal
PA33a 2 M 90 3rd ventricle normal
PA37a 16 M .85 Posterior fossa normal
PA40a 5 M 85 Optic nerve normal
PA43a 6 m M 90 Hypothalmus normal
PA44a 1 M 85 Optic nerve normal
PA45b 9 M .90 Posterior fossa normal
PA47a 8 F 90 Posterior fossa normal
PA48a 5 F 85 Cerebellum normal
PA49a 3 M Not known Vermis normal
PA50b Not known M 60–70 4th ventricle normal
PA51a 8 M Not known Right cerebella normal
PA52a 6 F Not known Posterior fossa normal
PA54a 6 F 100 Cerebellum normal
PA55a 8 F 75 Cerebellum normal
PA56a 18 M 80 Posterior fossa normal
PA57a 10 M 80 Posterior fossa normal
PA57b 13 M 100 Posterior fossa normal
PA58a 10 M 90 Not known normal
PA60a 7 F 80 Posterior fossa normal
Paediatric cases with abnormal CGH results
PA12a 17 F 85 Posterior fossa 16
PA25a 10 M 85 Optic chiasm 19
PA39a 11 F 90 Posterior fossa 15
PA42a 12 F 85 Left frontal lobe 17
PA53b 7 F 100 Supra sellar 17
Adult cases with normal CGH results
PA1a 33 F 85 Optic nerve normal
PA3a 32 M 80 Cerebellum normal
PA10a 20 F 85 Cerebellum normal
PA35a Not known F 80 Midline normal
PA41a 23 F 85 4th ventricle normal
Adult cases with abnormal CGH results
PA18a 33 F 85 Pineal region 11p33-pter, 19q34.1-qter, 116p, 117q21.3-pter, 119, 122
PA34a 48 F 90 Vermis 12p22-pter, 19q31-qter, 112q13.2-q23, 216qCGH analysis of pilocytic astrocytoma 1221
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aberrations the paediatric tumours always involved gain of whole
chromosomes. In adults gain of whole chromosomes or sub-
chromosomal regions was seen, as well as regional loss. The
difference in frequency and the types of aberration seen in the
adult cases is interesting. A higher incidence of malignant progres-
sion has been reported in adult PAs compared to paediatric PAs
(Giannini and Scheithauer, 1997).
The male to female ratio in our series was equal; there were 24
males and 24 females. However, four of the five paediatric
tumours and both of the adult tumours with detectable abnormali-
ties were from females. This finding is interesting and merits
further investigation. There was no association between the pres-
ence of abnormalities detectable by CGH and the anatomical
location of the tumours. The finding that one region of specimen
PA39a was normal, whereas another showed gain of chromosome
5 is also of interest, and is consistent with the notion of clonal
evolution in the neoplasm.
Our CGH results are consistent with data from previous cyto-
genetic studies. In the approximately 120 paediatric cases
analysed cytogenetically to date, gains have been seen on chromo-
somes 5 (four cases), 6 (two cases), 7 (nine cases), 12 (two cases),
17 (two cases), 19 (three cases) and 22 (three cases) (Jenkins et al,
1989; Karnes et al, 1992; Agamanolis and Malone, 1995; Debiec-
Rychter et al, 1995; White et al, 1995; Bhattacharjee et al, 1997;
Bigner et al, 1997; Zattara-Cannoni et al, 1998). In the approxi-
mately eight adult cases analysed cytogenetically, gains have been
seen for chromosomes 5 (two cases), 6 (three cases), 7 (two cases)
and 12 (one case). Gain of chromosome 7 is one of the most
common abnormalities in PA and has also been described as one of
the most characteristic aberrations in glioblastoma multiforme
(grade IV astrocytoma) (Liu et al, 1998). However, trisomy 7 has
also been reported in non-neoplastic tissue (including brain
tissue), both in vitro and in vivo, and the significance of its role in
oncogenesis remains controversial (Johansson et al, 1993).
We detected several abnormalities that have not previously been
reported in PA. These included gain of regions of chromosome 1p
and chromosome 2p, in cases PA18a and PA34a respectively. Our
most frequent finding (in three cases) was of gain on 9q, which
was detected in both adult tumours with abnormalities and in one
paediatric tumour (which showed gain of all of chromosome 9).
The minimal region of gain is 9q34.1-qter. A variety of genes are
located in this region including ABL (Abelson murine leukaemia),
VAV2 (Rho-family guanine-nucleotide exchange factor) and PBX3
(pre B-cell leukaemia transcription factor).
In those cases of PA in which no abnormalities are detectable
with CGH, it is not necessarily the case that no chromosomal aber-
rations are present. As CGH demonstrates loss or gain of DNA
sequences, balanced translocations remain undetected. In addition,
CGH will not detect polyploidy and will only detect DNA
sequence copy number changes if they differ from the average
copy number of chromosomes in the entire tumour specimen. It
should be noted however that polyploidy in PA has been reported
only in those rare cases which have undergone malignant transfor-
mation (Tomlinson et al, 1994; Mathew et al, 1996).
Abnormalities present in a small percentage of tumour cells
may also not be detectable by CGH. In a recent cytogenetic study
12 out of 24 cases of paediatric PA were reported to be mosaic, and
six of these cases showed random chromosomal gains and losses
(Zattara-Cannoni et al, 1998). In addition, PA tumours may
contain regions of DNA gain or loss that are beyond the resolution
of CGH. With metaphase chromosome targets the technique can
detect amplifications of approximately 2 MB (representing a
product of amplicon size and copy number increase) and regions
of DNA loss of 10 MB or greater (Kallioniemi et al, 1994).
In conclusion, we have demonstrated that major cytogenetic
abnormalities are relatively rare in PA. Interestingly, however, the
specimens from adults in our study showed more complex aberra-
tions than those from paediatric patients. In the small number of
abnormal cases no frequently occurring aberration is detectable,
although there is some consistency between our findings and those
from previous cytogenetic studies. Determination of mechanisms
underlying the development of PA may require detailed genotypic
analysis of tumour tissue, for example using developing DNA
microarray technology.
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